Kefir peptides mitigate bleomycin-induced pulmonary fibrosis in mice through modulating oxidative stress, inflammation and gut microbiota - 27/04/24
, Ying-Cheng Chen a, c, 1 , Chih-Ching Yen a, d , Hsiao-Ling Chen e, f, Min-Che Tung g, Hueng-Chuen Fan g, Chuan-Mu Chen a, h, ⁎ Abstract |
Background |
Idiopathic pulmonary fibrosis (IPF) is a progressive and life-threatening lung disease with high mortality rates. The limited availability of effective drugs for IPF treatment, coupled with concerns regarding adverse effects and restricted responsiveness, underscores the need for alternative approaches. Kefir peptides (KPs) have demonstrated antioxidative, anti-inflammatory, and antifibrotic properties, along with the capability to modulate gut microbiota. This study aims to investigate the impact of KPs on bleomycin-induced pulmonary fibrosis.
Methods |
Mice were treated with KPs for four days, followed by intratracheal injection of bleomycin for 21 days. Comprehensive assessments included pulmonary functional tests, micro-computed tomography (µ-CT), in vivo image analysis using MMPsense750, evaluation of inflammation- and fibrosis-related gene expression in lung tissue, and histopathological examinations. Furthermore, a detailed investigation of the gut microbiota community was performed using full-length 16 S rRNA sequencing in control mice, bleomycin-induced fibrotic mice, and KPs-pretreated fibrotic mice.
Results |
In KPs-pretreated bleomycin-induced lung fibrotic mice, notable outcomes included the absence of significant bodyweight loss, enhanced pulmonary functions, restored lung tissue architecture, and diminished thickening of inter-alveolar septa, as elucidated by morphological and histopathological analyses. Concurrently, a reduction in the expression levels of oxidative biomarkers, inflammatory factors, and fibrotic indicators was observed. Moreover, 16 S rRNA sequencing demonstrated that KPs pretreatment induced alterations in the relative abundances of gut microbiota, notably affecting Barnesiella_intestinihominis, Kineothrix_alysoides, and Clostridium_viride.
Conclusions |
Kefir peptides exerted preventive effects, protecting mice against bleomycin-induced lung oxidative stress, inflammation, and fibrosis. These effects are likely linked to modifications in the gut microbiota community. The findings highlight the therapeutic potential of KPs in mitigating pulmonary fibrosis and advocate for additional exploration in clinical settings.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Idiopathic pulmonary fibrosis (IPF), a severe lung condition with high mortality, poses a significant health threat. |
• | A murine model effectively mimics IPF symptoms three weeks post intratracheal bleomycin administration. |
• | Kefir peptides (KPs) alleviate bleomycin-induced lung injury, improving respiratory function and reducing fibrosis. |
• | KPs offer multifaceted defense, combating oxidative stress, inflammation, and profibrotic factors in pulmonary fibrosis. |
• | KPs induce structural changes in the gut microbiota of bleomycin-induced pulmonary fibrotic mice. |
Keywords : Kefir peptides (KPs), Idiopathic pulmonary fibrosis (IPF), Inflammation, Bleomycin, Gut microbiota community
Plan
Vol 174
Article 116431- mai 2024 Retour au numéro
Article précédent
- An anti-GD2 aptamer-based bifunctional spherical nucleic acid nanoplatform for synergistic therapy targeting MDM2 for retinoblastoma
- Shijing Wang, Yan Zhao, Fei Yao, Pengxue Wei, Lan Ma, Shaochong Zhang
- Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition
- Sha Chen, Kenneth Overberg, Zakiya Ghouse, Markus W. Hollmann, Nina C. Weber, Ruben Coronel, Coert J. Zuurbier
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?